Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

DCDavid CunninghamUFUmar FarooqTFTatyana Feldman

Discussion

Loading...

Member takes

Overview

Pivotal trial finds 42% of complete responders maintained remission after over 4 years, highlighting safety and efficacy of epcoritamab.

Key Points

  • To evaluate the long-term efficacy and safety of epcoritamab monotherapy in patients with relapsed or refractory large B-cell lymphoma.
  • Participants included adults with R/R CD20+ LBCL who received epcoritamab in the pivotal EPCORE NHL-1 trial.
  • Patients had received ≥2 prior lines of systemic therapy and were treated subcutaneously.
  • Key endpoints included overall response rate and median follow-up duration.
  • 59% of patients achieved a response; 41% achieved a complete response (CR).
  • Median duration of CR was 37.7 months, with 42% of CRs ongoing after 4 years.
  • Median overall survival was 18.5 months; 32% of patients remained alive at 4 years.

Cite This Study

Cunningham et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d515https://doi.org/10.1182/blood-2025-5513
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial2026 · 4 citations
  2. 2Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response2025
  3. 3Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).2024 · 9 citations
  4. 4Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial2025 · 4 citations
  5. 5Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 2 citations